Skip to content
Politically.com Search all
Menu

2026 · 2nd Quarter (Apr 1 - June 30)

STEALTH BIOTHERAPEUTICS INC.

Filed by STEALTH BIOTHERAPEUTICS INC..

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 20, 2026
Income
Not reported
Expenses
$120,000.00
Filing UUID
4bf1dcbb-a7e0-435c-9891-fad540d3b4d0
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

H.R. 1262/S. 932 - Mikaela Naylon Give Kids a Chance Act General discussions about ultra-rare diseases General discussions about ultra-rare disease drug development General discussions about regulatory reform, including scientific-focused drug development meetings General discussions about mitochondrial diseases H.R. 1532/S. 822, the Scientific EXPERT Act of 2025FDA Rare Disease Innovation Hub Fiscal Year 2026 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (H.R. 4121 / S. 2256) H.R.6280/S.3607 - Access to Genetic Counselor Services Act of 2025/Access to Genetic Counselor Services Act of 2026 H.R.4709 - Newborn Screening Saves Lives Reauthorization Act of 2025 General discussions about genetic testing, diagnostics General discussions about accelerated approval pathway (AAP)

Literal federal measure citations: H.R. 1262, S. 932, H.R. 1532, S. 822, H.R. 4121, S. 2256, H.R.6280, S.3607, H.R.4709

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.